Phase 2/3 study in advanced/metastatic epithelial ovarian cancer2019-04-08T11:41:23+00:00

Project Description

Phase 2/3 study in advanced/metastatic epithelial ovarian cancer

Brief

Cancerous epithelial ovarian tumors, called carcinomas, are the most current ovarian cancer. Epithelial tumors usually start from the cells that cover the outer surface of the ovary.

R.G.L has been mandated by a biotechnology company to lead an international and competitive phase 2/3 study in Israel to prove the efficacy and safety of their molecule in epithelial ovarian cancer.

Goals

  • To find 3 medical centers with a high rate of patients recruitment
  • To sign with all 3 centers a Clinical Trial Agreement and negotiate a budget per patient according to Sponsor’s guidelines and recommendations 
  • To obtain Local Ethical Committee approvals in the conduct of the Trial 
  • To obtain Ministry of Health’s approval in the conduct of the Trial for Israel
  • To recruit 100% of the recruitment patient potential (25 patients) in 12 months, 

Want To Work With Us?

WE WILL BE HAPPY TO WORK WITH YOU.

Contact Us